stockrowRegencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Return on invested capital
Regencell Bioscience Holdings Limited's return on invested capital over the twelve months to 30 June 2026 was 0.00%. Over the past ten years it has ranged from −1,149.7% (fiscal 2024) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 1,149.68 |
| FY2024 | −1,149.7% | (226.21) |
| FY2023 | −923.5% | (206.33) |
| FY2022 | −717.1% | (717.14) |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | 27.2% |
| PBH Prestige Consumer Healthcare Inc. compare | 9.59% |
| TRLV Trulieve Cannabis Corp. compare | 0.00% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited | 0.00% |
| ALVO Alvotech compare | 0.00% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 0.00% |
| PRGO Perrigo Company plc compare | −19.0% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)